Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and Apatinib Neoadjuvant Therapy in Advanced Ovarian Cancer
NCT05597527Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib, Rivoceranib in ovarian cancer, sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05597527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597527.